<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32759248</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan.</ArticleTitle><Pagination><StartPage>e037753</StartPage><MedlinePgn>e037753</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e037753</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2020-037753</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis (ALS) is a devastating, progressive disease that causes degeneration of the motor neurons leading to paresis of the bulbar and the skeletal musculature. The pathogenesis of ALS remains unknown. We will test the hypothesis that the complement system is involved in the pathophysiology of ALS. This protocol article describes our efforts to establish a national Danish ALS biobank. The primary aim is to obtain biological material from patients with ALS for the current study as well as for future studies.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">We intend to establish an observational ALS biobank; some of the material from this biobank will be used for a prospective, observational case-control study. The participants are patients with ALS, neurologically healthy controls and non-ALS neurological controls. Each participant consents to be interviewed and to donate blood and cerebrospinal fluid to the biobank. Analysis of the complement system will be carried out on the three groups of patients and compared.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">The project has been approved by the Committees on Health Research Ethics in the Capital Region of Denmark (Approval number H-16017145) and the Danish Data Protection Agency (file number 2012-58-0004). All results will be published in peer-reviewed, medical journals and presented at scientific conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT02869048.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kj&#xe6;ldgaard</LastName><ForeName>Anne-Lene</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-7197-8298</Identifier><AffiliationInfo><Affiliation>Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark akja0044@regionh.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pilely</LastName><ForeName>Katrine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Karsten Skovgaard</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauritsen</LastName><ForeName>Anne &#xd8;berg</ForeName><Initials>A&#xd8;</Initials><AffiliationInfo><Affiliation>Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Stephen W&#xf8;rlich</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Neurology, The Neuroscience Centre, Rigshospitalet, Glostrup, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neuroanaesthesiology, The Neuroscience Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garred</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology Section 7631, Diagnostic Centre, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02869048</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018070" MajorTopicYN="N">Biological Specimen Banks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult neurology</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">neuropathology</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32759248</ArticleId><ArticleId IdType="pmc">PMC7409992</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2020-037753</ArticleId><ArticleId IdType="pii">bmjopen-2020-037753</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007;6:994&#x2013;1003. 10.1016/S1474-4422(07)70265-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70265-X</ArticleId><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. . Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 2013;41:118&#x2013;30. 10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD. Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol 2015;69:5.67.1-5.67.21. 10.1002/0471141755.ph0567s69</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471141755.ph0567s69</ArticleId><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kj&#xe6;ldgaard A-L, Pilely K, Olsen KS, et al. . Amyotrophic lateral sclerosis: the complement and inflammatory hypothesis. Mol Immunol 2018;102:14&#x2013;25. 10.1016/j.molimm.2018.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2018.06.007</ArticleId><ArticleId IdType="pubmed">29933890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia El Idrissi N, Bosch S, Ramaglia V, et al. . Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflammation 2016;13:72. 10.1186/s12974-016-0538-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0538-2</ArticleId><ArticleId IdType="pmc">PMC4823861</ArticleId><ArticleId IdType="pubmed">27056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich B, El Idrissi NB, Donev RM, et al. . Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J Neuroimmunol 2011;235:104&#x2013;9. 10.1016/j.jneuroim.2011.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.03.011</ArticleId><ArticleId IdType="pubmed">21501881</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SE, Hanton AM, Stefanou SN, et al. . Revisiting the role of the innate immune complement system in ALS. Neurobiol Dis 2019;127:223&#x2013;32. 10.1016/j.nbd.2019.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.03.003</ArticleId><ArticleId IdType="pubmed">30849511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A-W, Tetzlaff JM, G&#xf8;tzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e7586</ArticleId><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;9. 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). J Neurol Sci 1999;169:13&#x2013;21. 10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayarri-Olmos R, Kirketerp-Moller N, P&#xe9;rez-Al&#xf3;s L, et al. . Development of a quantitative assay for the characterization of human Collectin-11 (CL-11, CL-K1). Front Immunol 2018;9:2238. 10.3389/fimmu.2018.02238</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02238</ArticleId><ArticleId IdType="pmc">PMC6172411</ArticleId><ArticleId IdType="pubmed">30323815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastrup-Birk S, Skjoedt M-O, Munthe-Fog L, et al. . Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 2013;8:e73119. 10.1371/journal.pone.0073119</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073119</ArticleId><ArticleId IdType="pmc">PMC3767672</ArticleId><ArticleId IdType="pubmed">24039869</ArticleId></ArticleIdList></Reference><Reference><Citation>Skjoedt M-O, Palarasah Y, Munthe-Fog L, et al. . MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with ficolin-3 and regulates ficolin-3 mediated complement activation. Immunobiology 2010;215:921&#x2013;31. 10.1016/j.imbio.2009.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2009.10.006</ArticleId><ArticleId IdType="pubmed">19939495</ArticleId></ArticleIdList></Reference><Reference><Citation>Skjoedt M-O, Hummelshoj T, Palarasah Y, et al. . Serum concentration and interaction properties of MBL/ficolin associated protein-1. Immunobiology 2011;216:625&#x2013;32. 10.1016/j.imbio.2010.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2010.09.011</ArticleId><ArticleId IdType="pubmed">21035894</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelen MA, Roos A, Wieslander J, et al. . Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005;296:187&#x2013;98. 10.1016/j.jim.2004.11.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2004.11.016</ArticleId><ArticleId IdType="pubmed">15680163</ArticleId></ArticleIdList></Reference><Reference><Citation>Hein E, Honor&#xe9; C, Skjoedt M-O, et al. . Functional analysis of ficolin-3 mediated complement activation. PLoS One 2010;5:e15443. 10.1371/journal.pone.0015443</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015443</ArticleId><ArticleId IdType="pmc">PMC2978102</ArticleId><ArticleId IdType="pubmed">21085669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilely K, Skjoedt M-O, Nielsen C, et al. . A specific assay for quantification of human C4c by use of an anti-C4c monoclonal antibody. J Immunol Methods 2014;405:87&#x2013;96. 10.1016/j.jim.2014.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2014.01.011</ArticleId><ArticleId IdType="pubmed">24472768</ArticleId></ArticleIdList></Reference><Reference><Citation>Garred P, Mollnes TE, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 1988;27:329&#x2013;35. 10.1111/j.1365-3083.1988.tb02354.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1988.tb02354.x</ArticleId><ArticleId IdType="pubmed">2451274</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollnes TE, Lea T, Fr&#xf8;land SS, et al. . Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985;22:197&#x2013;202. 10.1111/j.1365-3083.1985.tb01871.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1985.tb01871.x</ArticleId><ArticleId IdType="pubmed">2412280</ArticleId></ArticleIdList></Reference><Reference><Citation>Garred P, Madsen HO, Kurtzhals JA, et al. . Diallelic polymorphism may explain variations of the blood concentration of mannan-binding protein in Eskimos, but not in black Africans. Eur J Immunogenet 1992;19:403&#x2013;12. 10.1111/j.1744-313X.1992.tb00083.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1744-313X.1992.tb00083.x</ArticleId><ArticleId IdType="pubmed">1477092</ArticleId></ArticleIdList></Reference><Reference><Citation>Munthe-Fog L, Hummelsh&#xf8;j T, Hansen BE, et al. . The impact of FCN2 polymorphisms and haplotypes on the ficolin-2 serum levels. Scand J Immunol 2007;65:383&#x2013;92. 10.1111/j.1365-3083.2007.01915.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.2007.01915.x</ArticleId><ArticleId IdType="pubmed">17386030</ArticleId></ArticleIdList></Reference><Reference><Citation>Munthe-Fog L, Hummelsh&#xf8;j T, Ma YJ, et al. . Characterization of a polymorphism in the coding sequence of FCN3 resulting in a ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 2008;45:2660&#x2013;6. 10.1016/j.molimm.2007.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.12.012</ArticleId><ArticleId IdType="pubmed">18261799</ArticleId></ArticleIdList></Reference><Reference><Citation>Munthe-Fog L, Hummelshoj T, Honor&#xe9; C, et al. . Variation in FCN1 affects biosynthesis of ficolin-1 and is associated with outcome of systemic inflammation. Genes Immun 2012;13:515&#x2013;22. 10.1038/gene.2012.27</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2012.27</ArticleId><ArticleId IdType="pubmed">22673311</ArticleId></ArticleIdList></Reference><Reference><Citation>Overgaard K, Werdelin L, S&#xf8;rensen H, et al. . Cytotoxic activity in plasma from patients with amyotrophic lateral sclerosis. Neurology 1991;41:925&#x2013;7. 10.1212/WNL.41.6.925</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.41.6.925</ArticleId><ArticleId IdType="pubmed">2046943</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage PBG. Statistical methods for medical researchers. Blackwell, 1994.</Citation></Reference><Reference><Citation>Sherman AV, Gubitz AK, Al-Chalabi A, et al. . Infrastructure resources for clinical research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:53&#x2013;61. 10.3109/21678421.2013.779058</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.779058</ArticleId><ArticleId IdType="pubmed">23678880</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ricklin D, Lambris JD. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci U S A 2017;114:10948&#x2013;53. 10.1073/pnas.1707364114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707364114</ArticleId><ArticleId IdType="pmc">PMC5642699</ArticleId><ArticleId IdType="pubmed">28973891</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HA, Lee JD, Lee KM, et al. . Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Skelet Muscle 2017;7:10. 10.1186/s13395-017-0128-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-017-0128-8</ArticleId><ArticleId IdType="pmc">PMC5455206</ArticleId><ArticleId IdType="pubmed">28571586</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Schmidt SAJ, Sandegaard JL, et al. . The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 2015;7:449&#x2013;90. 10.2147/CLEP.S91125</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S91125</ArticleId><ArticleId IdType="pmc">PMC4655913</ArticleId><ArticleId IdType="pubmed">26604824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowicka N, Juranek J, Juranek JK, et al. . Risk factors and emerging therapies in amyotrophic lateral sclerosis. Int J Mol Sci 2019;20. 10.3390/ijms20112616. [Epub ahead of print: 28 May 2019].</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112616</ArticleId><ArticleId IdType="pmc">PMC6600314</ArticleId><ArticleId IdType="pubmed">31141951</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor-Rowan M, Wilson A, Dawson J, et al. . Functional assessment for acute stroke trials: properties, analysis, and application. Front Neurol 2018;9:191&#x2013;91. 10.3389/fneur.2018.00191</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00191</ArticleId><ArticleId IdType="pmc">PMC5879151</ArticleId><ArticleId IdType="pubmed">29632511</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, et al. . Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182&#x2013;94. 10.1016/S1474-4422(16)30199-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30199-5</ArticleId><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>